SecBot SecBot
PRESS-RELEASE ·Filed May 5, 2026

IRON

Disc Medicine Inc
NEUTRAL
Impact 5/10
Horizonmonths Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight • Neutral

The Q1 earnings beat is marginal and overshadowed by rising operating losses. The stock will trade on pipeline catalysts: watch for the FDA Type A meeting outcome in Q2 and the Phase 3 APOLLO topline data in Q4 2026, which are the primary value drivers. The $730M cash runway into 2029 removes near-term financing risk.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$67.59
T+0 close · May 5, 2026 · via day close
Latest settled
+17.19%
T+60 · $79.21
Vs SPY
+14.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 5 $67.59entry
  2. T+1 · 7mo ago +1.57%α +0.18% · $68.65
  3. T+5 · 6mo ago +2.43%α +0.44% · $69.23
  4. T+20 · 6mo ago +0.61%α −4.35% · $68.00
  5. T+60 · 4mo ago +17.19%α +14.45% · $79.21
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Disc Medicine reported Q1 2026 EPS of -$1.65, slightly beating the -$1.73 consensus by 4.6%, but net loss widened to $63.5M from $34.1M a year ago on higher R&D and SG&A costs. The key catalyst is the completed enrollment of the Phase 3 APOLLO trial for bitopertin in EPP, with topline data expected in Q4 2026, which could support an FDA resubmission by mid-2027.

Key Financial Metrics

EPS
−$1.65
est −$1.73 · +4.6%
Rating
in line

Key Facts

  • Q1 2026 EPS of -$1.65 vs consensus -$1.73 (4.6% beat)
  • Net loss widened to $63.5M from $34.1M YoY, driven by higher R&D ($45.9M vs $27.8M) and SG&A ($23.6M vs $12.2M)
  • Cash, cash equivalents, and marketable securities of $730.2M, providing runway into 2029
  • Phase 3 APOLLO trial of bitopertin in EPP fully enrolled (183 patients); topline data expected Q4 2026
  • Type A meeting with FDA scheduled for Q2 2026 to discuss bitopertin CRL response; potential FDA decision by mid-2027
  • Updated Phase 2 data for DISC-0974 in MF anemia to be presented at ASCO in June 2026
  • Phase 2 data for DISC-3405 in PV and Phase 1b data in SCD expected Q4 2026

Financial Impact

Net loss of $63.5M in Q1 2026 vs $34.1M in Q1 2025; cash burn of ~$61M in the quarter

net losscash positionR&D expensesSG&A expenses

Risk Factors

  • Bitopertin Phase 3 APOLLO trial failure or disappointing topline data in Q4 2026
  • FDA Type A meeting could result in additional clinical requirements, delaying bitopertin approval
  • Rising operating expenses without near-term revenue could pressure valuation if pipeline milestones slip

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
95% bullish (19 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3287684

Track record

43 reports on IRON

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +20.07% at T+20 after the Sep 3, 2026 report. 11 of 16 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $87.08 Now $76.59 −12.05% settles Dec 10
  2. Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $78.91 Now $76.59 +2.94% settles Dec 7
  3. Nov 5, 202611d ago 8-K Neutral 5/10 No price data
  4. Nov 5, 202611d ago Press Release Bullish 7/10 Entry $78.47 Now $76.59 −2.40% settles Dec 4
  5. Nov 4, 202612d ago Press Release Neutral 3/10 Entry $83.28 Now $76.59 −8.03% settles Dec 3
  6. Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $81.16 Now $76.59 −5.63% settles Dec 2
  7. Oct 26, 202621d ago SC 13D/A Neutral 3/10 Entry $79.90 Now $76.59 −4.14% settles Nov 24
  8. Oct 22, 202625d ago 8-K Bearish 6/10 Entry $74.51 Now $76.59 −2.79% settles Nov 20
  9. Oct 21, 202626d ago 424B5 Bearish 6/10 Entry $75.03 Now $76.59 −2.08% settles Nov 19
  10. Oct 21, 202626d ago 144 Neutral 2/10 Entry $75.03 Now $76.59 +2.08% settles Nov 19
Showing 10 of 43

US Market Status

Market Closed · Opens Wed (10h 12m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026